- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05355415
Adaptive Optics Imaging of Outer Retinal Diseases
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objective: The objective of the study is to collect adaptive optics (AO) retinal images from human subjects with outer retinal diseases (diseases of the outer retina including photoreceptor, retinal pigment epithelium (RPE), basement membrane or choroidal pathologies) to develop new diagnostic methods, biomarkers, and clinical endpoints.
Study Population: Up to fifty (50) healthy volunteers without eye disease (Cohort 1) and up to fifty (50) affected participants with any type of outer retinal disease (Cohort 2) will be enrolled.
Design: This is a longitudinal study protocol where participants will be imaged with investigational multimodal AO (mAO) retinal imaging systems that include optical coherence tomography (OCT) and scanning laser ophthalmoscopy (SLO) channels over three years. High resolution OCT and SLO videos will be collected while the instruments automatically detect and correct for image distortion caused by ocular aberrations. In general, videos of different retinal cellular structures will be acquired from several retinal locations using various imaging modes.
Outcome Measures: The primary outcomes for this protocol are development of new diagnostic methods and disease biomarkers, investigation of cellular morphological and functional changes due to various outer retinal diseases, and development of new AO clinical endpoints for novel therapies.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Daniel X Hammer, Ph.D.
- Phone Number: 301-796-9320
- Email: daniel.hammer@fda.hhs.gov
Study Contact Backup
- Name: Zhuolin Liu, Ph.D.
- Phone Number: 301-796-7914
- Email: zhuolin.liu@fda.hhs.gov
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20810
- Recruiting
- NIH Clinical Center
-
Contact:
- Catherine Cukras, M.D., Ph.D.
- Phone Number: 301-435-5061
- Email: cukrasc@nei.nih.gov
-
Silver Spring, Maryland, United States, 20993
- Recruiting
- Food and Drug Administration
-
Contact:
- Daniel X Hammer, Ph.D.
- Phone Number: 301-796-9320
- Email: daniel.hammer@fda.hhs.gov
-
Contact:
- Zhuolin Liu, Ph.D.
- Phone Number: 301-796-7914
- Email: zhuolin.liu@fda.hhs.gov
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Are 21 years of age or older,
- Have the ability to cooperate with instructions during adaptive optics imaging (similar to instructions given during a clinical eye exam),
- Have the ability to understand and sign an informed consent. (Non-English speaking participants will not be enrolled into the study), and
- Have been diagnosed with outer retinal disease or condition (Cohort 2).
Exclusion Criteria:
- Have a condition which prevents adequate images from being obtained (e.g. unstable fixation or media opacity),
- Have visual correction outside of the range +4 diopters (D) to -8 D,
- Have a history of adverse reaction to mydriatic drops,
- Have a predisposition to (i.e., narrow iridocorneal angle) or any history of acute angle closure glaucoma (AACG), or
- Are working under the direct supervision of Drs. Hammer, Cukras and Liu, or any of the NIH/NEI AIs.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Outer retinal disease
Subjects with outer retinal disease affecting the photoreceptor-retinal pigment epithelium complex will be classified by clinical exam by an experienced retina specialist.
Outer retinal disease subjects will undergo adaptive optics (AO) imaging of several macular locations.
|
Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging
|
Healthy control
Age-matched healthy control subjects will undergo the same AO imaging procedures as subjects with outer retinal diseases.
|
Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Photoreceptor (PR) density
Time Frame: PR density will be calculated once at the AO imaging session in which PRs are the target.
|
PR density will be calculated at specific retinal eccentricities from cells counted in average AO-OCT volumes or average AOSLO frames.
|
PR density will be calculated once at the AO imaging session in which PRs are the target.
|
Retinal pigment epithelial (RPE) cell density
Time Frame: RPE cell density will be calculated once at the AO imaging session in which RPE cells are the target.
|
RPE cell density will be calculated at specific retinal eccentricities from cells counted in average AO-OCT volumes.
|
RPE cell density will be calculated once at the AO imaging session in which RPE cells are the target.
|
RPE cell organelle motility
Time Frame: RPE motility will be calculated once at the AO imaging session in which RPE cells are the target. For the reproducibility portion of the study, RPE organelle motility will be quantified three times separated by 1-2 weeks.
|
RPE cell organelle motility will be calculated from the decorrelation time constant for cells segmented from a sequence of AO-OCT volumes.
|
RPE motility will be calculated once at the AO imaging session in which RPE cells are the target. For the reproducibility portion of the study, RPE organelle motility will be quantified three times separated by 1-2 weeks.
|
PR cell function
Time Frame: PR function will be calculated once at the AO imaging session in which PR cells are stimulated. For the reproducibility portion of the study, PR cell function will be quantified three times separated by 1-2 weeks.
|
Photoreceptor cell (cone) function will be measured from phase changes between inner segment - outer segment junction and cone outer segment tip signals in a sequence of AO-OCT volumes collected during visible light stimulation.
|
PR function will be calculated once at the AO imaging session in which PR cells are stimulated. For the reproducibility portion of the study, PR cell function will be quantified three times separated by 1-2 weeks.
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Daniel X Hammer, Ph.D., Food and Drug Administration (FDA)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Eye Diseases
- Neurologic Manifestations
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Otorhinolaryngologic Diseases
- Ear Diseases
- Eye Diseases, Hereditary
- Retinal Dystrophies
- Sensation Disorders
- Abnormalities, Multiple
- Hearing Disorders
- Vision Disorders
- Deaf-Blind Disorders
- Hearing Loss, Sensorineural
- Blindness
- Hearing Loss
- Deafness
- Macular Degeneration
- Retinal Diseases
- Retinitis
- Retinitis Pigmentosa
- Cone-Rod Dystrophies
- Usher Syndromes
- Retinal Degeneration
- Cone Dystrophy
Other Study ID Numbers
- 2019-CDRH-074
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Age-Related Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hoffmann-La RocheRecruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
Ocular Therapeutix, Inc.Duke University; FortreaRecruitingNeovascular Age-Related Macular DegenerationUnited States
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Ocular Therapeutix, Inc.CompletedNeovascular Age-Related Macular DegenerationUnited States
-
Novartis PharmaceuticalsWithdrawn
Clinical Trials on Adaptive optics imaging
-
Food and Drug Administration (FDA)University of Maryland, BaltimoreRecruiting
-
Indiana UniversityRecruitingPigmentary Retinopathy | Pentosan Polysulfate Sodium Maculopathy | Pigmentary Maculopathy | Toxic Maculopathy | Interstitial Cystitis, ChronicUnited States
-
Centre Hospitalier National d'Ophtalmologie des...RecruitingStroke | Glaucoma | Hypertension | Diabetes | Retinal Degeneration | Macular Edema | Retinitis Pigmentosa | Trauma | Dry Eye | Keratoconus | Retinal Detachment | Corneal Dystrophy | Vascular Inflammation | Macular Dystrophy | Maculopathy, Age RelatedFrance
-
The Hospital for Sick ChildrenRecruitingGenetic Disease | Inherited DiseaseCanada
-
Institut National de la Santé Et de la Recherche...BiogenUnknownNervous System Diseases | Progressive Multiple Sclerosis | Multiple Sclerosis | Eye Diseases | Optic Neuritis | Optic Nerve Diseases | Relapsing Remitting Multiple SclerosisFrance
-
Johnson & Johnson Vision Care, Inc.Recruiting
-
University of Maryland, BaltimoreRecruiting
-
University Hospital, ToulouseCentre de Référence National du KératocôneTerminated
-
Icahn School of Medicine at Mount SinaiUniversity of California, Los Angeles; National Eye Institute (NEI)Recruiting